**Name of journal:** ***World Journal of*** ***Gastroenterology***

**Manuscript NO: 32996**

Manuscript type: Minireviews

Colorectal cancer population screening programs worldwide in 2016: An update

Navarro *et al.* Colorectal cancer population screening programs worldwide

Mercedes Navarro, Andrea Nicolas, Angel Ferrandez, Angel Lanas

**Mercedes Navarro, Angel Ferrandez, Angel Lanas,** Service of Digestive Diseases, University Clinic Hospital Lozano Blesa, Zaragoza 50009, Spain

**Andrea Nicolas, Angel Lanas,** University of Zaragoza, Zaragoza 50009, Spain

**Angel Lanas,** Aragón Health Research Institute (IIS Aragón), Zaragoza 50009, Spain

**Angel Lanas,**  CIBERehd, Zaragoza 50009, Spain

**Author contributions**: Lanas A design the outline of the paper and revised the subsequent drafts of the paper; Nicolas A and Navarro M performed the research; Navarro M, Ferrandez A wrote the drafts of the paper; all coauthors provided critical revision for important intellectual content.

**Conflict-of-interest statement:** Authors declare no conflicts of interest for this article.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Correspondence to: Angel Lanas, MD, DSc, AGAF, FACG, Professor, Chairman,** Gastroenterology, University Hospital Lozano Blesa, Av San Juan Bosco 15, Zaragoza 50009, Spain. [alanas@unizar.es](mailto:alanas@unizar.es)

**Telephone**:+34-976-765700

**Fax**: +34-976-565995

**Received:** January 26, 2017

**Peer-review started:** February 2, 2017

**First decision:** March 3, 2017

**Revised:** March 21, 2017

**Accepted:** May 4, 2017

**Article in press:**

**Published online:**

Abstract

Colorectal cancer (CRC) is the third most commonly diagnosed cancer in the world. The incidence and mortality show wide geographical variations. Screening is recommended to reduce both incidence and mortality. However, there are significant differences among studies in implementation strategies and detection. This review aimed to present the results and strategies of different screening programs worldwide. We reviewed the literature on national and international screening programs published in PubMed, on web pages, and in clinical guidelines. CRC Screening programs are currently underway in most European countries, Canada, specific regions in North and South America, Asia, and Oceania. The most extensive screening strategies were based on fecal occult blood testing, and more recently, the fecal immunochemical test (FIT). Participation in screening has varied greatly among different programs. The Netherlands showed the highest participation rate (68.2%) and some areas of Canada showed the lowest (16%). Participation rates were highest among women and in programs that used the FIT test. Men exhibited the greatest number of positive results. The FIT test has been the most widely used screening program worldwide. The advent of this test has increased participation rates and the detection of positive results.

**Key words:** Colorectal cancer; Colorectal cancer screening; Fecal occult blood test; Fecal inmmunochemical test; Colonoscopy

**© The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Colorectal cancer is the third most commonly diagnosed cancer worldwide. The incidence and mortality show wide geographical variations across the world. Screening is recommended to reduce both, however, there are significant differences among studies in implementation strategies and detection. This review aimed to present the results and strategies of different screening programs worldwide.

Navarro M, Nicolas A, Ferrandez A, Lanas A. Colorectal cancer population screening programs worldwide in 2016: An update. *World J Gastroenterol* 2017; In press

**INTRODUCTION**

Colorectal Cancer (CRC) is one the most commonly diagnosed cancers worldwide. Among men with cancer, CRC ranked third in prevalence (746000 cases, 10% of the total male population), after lung and prostate cancers. Among women with cancer, CRC ranked second in prevalence (614000 cases, 9.2% of the total female population), after breast cancer. CRC incidence and mortality show wide geographical variations across the world. When comparing age-standardized incidence rates (ASRis) of CRC in different countries, we found the highest rates in Australia and New Zealand, and the lowest rates in Western Africa[1].

Nearly 55% of CRC cases occur in developed regions, but CRC-related mortality is highest in less developed countries (including regions of Africa). This poor survival is probably due to the lack of available health resources. However, high- and low-income countries also show large variations in the proportion of the population included in CRC registries. These variations may arise from underdiagnoses, due to local medical and economic situations[2].

In many regions, the risk of developing CRC is around 5%, and of those patients, 45% will die despite treatment[3]. According to GLOBOCAN data, 694000 individuals died in 2012 from CRC worldwide (374000 men and 320000 women). Mortality rates show less variability than incidence rates; the highest estimated CRC-related mortality rates in both sexes were found in Central and Eastern Europe, and the lowest were found in Western Africa[1].

In Europe, there are huge variations in the ASRis of CRC; the lowest incidences were observed among men and women in Bosnia Herzegovina (30 per 100000 and 19 per 100000, respectively) and in Albania (13 and 11 per 100000 respectively). Among men, the highest incidences were observed in Slovakia, Hungary, and the Czech Republic. Among women, the highest incidences were found in Norway, Denmark, and Holland[1]. Although mortality rates are generally geographically similar to incidence rates, mortality is sometimes high in countries with relatively low incidence rates (Moldavia, Russia, Montenegro, Poland, and Lithuania) [4]. In North America, the ASRi of CRC was estimated to be 26.1 per 100000. In 2016, the American Cancer Society estimated that 134490 new CRC cases would be diagnosed in individuals of both sexes, and that 49190 individuals would die from CRC in the United States[5]. In the Eastern Mediterranean region, the highest CRC incidence was found in Israel (36 per 100000), followed by Jordan and Kazakhstan (26 and 23 per 100000, respectively). The highest mortality rates were found in Jordan, followed by Kazakhstan, Armenia, and Israel. In the Asian Pacific region, the incidence of CRC varies among regions. The highest incidence was reported in South Korea (ASRi: 45 per 100000). Singapore and Japan also had high incidence rates (ASRis: 34 and 32 per 100000, respectively). Compared to those regions, other countries, like India, have much lower ASRis (6 per 100000) and age-standardized mortality rates (ASRm: 5 per 100000)[4].

CRC qualifies for screening according to the criteria established by Wilson and Jungner as the “gold standard of screening assessment”[6,7,8]. The criteria that CRC fulfills include its high incidence rate, its long preclinical phase, its recognizable and tractable precursor, and the correlation between the tumor stage and mortality rate. Although the value of the Wilson and Jungner criteria remains undisputed to this day, newer policy tools are now available (Table 1).

Screening for CRC appears to be cost-effective compared to no screening[10]. However, CRC screening programs must be adapted to the risk of each population. An average-risk population is defined as a population of individuals aged 50 years or older, with no additional risk factors. The recommended screening for the average-risk population is one of the following: an annual or biennial fecal immunochemical test (FIT); sigmoidoscopy every 5 years; or colonoscopy every 10 years. When subgroups are identified and characterized with a higher-than-average incidence of colorectal neoplasia, it is necessary to increase the screening frequency to achieve program cost-effectiveness[11]. Despite recommendations, screening is currently offered to only a small proportion of the population.

In this review, we evaluated the results of 17 screening programs. We obtained ASRis and ASRms in the different countries reviewed from the website: www.globocan.iarc.fr. A literature search was conducted in PUBMED with the following keywords: Screening, Colorectal Cancer, Bowel cancer, guidelines, programmes, program, results, FIT, guaiac, first round, pilot, rounds, Europe/ United Kingdom/ Ireland/ The Netherlands/ Lithuania/ Italy/ Croatia/ Czech Republic/ Slovenia/ France/ Canada/ California/ USA/ Korea/ Australia/ Thailandia/ Taiwan/ Chile. CRC screening program characteristics were also collected from national governmental websites. To evaluate and compare screening programs, we used universally applicable CRC screening indicators.

CRC SCREENING TESTS

*Stool tests*

It has been established that CRC mortality could be reduced by screening with periodic fecal occult blood tests (FOBTs), followed by colonoscopy when the results were positive. A systematic review published in 2008, which included 4 clinical controlled trials involving over 300000 participants, found that screening with FOBT reduced the relative risk (RR) of CRC mortality by 16%, without adjustment, and by 25% after adjusting for screening attendance[12]. The follow-up of those patients showed that the effect of screening was reduced CRC-mortality, and this effect persisted for over 30 years[13]. A reduction in the RR of CRC incidence was also detected in follow-up, mainly due to the removal of adenomatous polyps. This effect was greater among individuals that received annual screenings (20% RR) than among those that received biennial (17%) screenings[14].

Currently, there are two different tests available: the FIT and the guaiac fecal occult blood test (G-FOBT). The FIT achieved significantly higher detection rates for advanced adenomas and CRC than the G-FOBT. Although the FIT was more sensitive than the G-FOBT (61% *vs* 23.8%, respectively), its specificity was slightly lower (95.1% *vs* 97.7%, respectively) [15,16]. Participation rates appeared to be higher in screening programs that used FIT compared to those that used G-FOBT[15]. This issue is probably related to the facts that FIT does not require dietary restrictions (due to its specificity to human hemoglobin [Hb]) and that only one sample is needed in most screening programs[16]. Additionally, FIT offers quantitative results (ng Hb per ml buffer or μg Hb per g feces) and an automated reading of the results. The cut-off value for the amount of Hb detected can be predetermined by the investigator. Several cut-off values have been used with different sensitivity and specificity rates. The investigator can adjust the cut-off value to limit the number of colonoscopies required, and thus, avoid overextending the available endoscopic resources. An optimum cut-off value has not been established; therefore, the choice should be based on the availability of endoscopic resources, the epidemiology of CRC in the study population, and the expected participation in the program[17]. Values between 20 and 30 μg/g are recommended when the Health Care System can accommodate colonoscopies for approximately 5% (expected FIT positivity rate) of the population study (aged 50-74 years)[18].

Based on current evidence, the FIT has been recommended as the first option for detecting fecal occult blood in CRC screening[19]. Most European countries with an organized screening program are currently using the FIT. This test has replaced the G-FOBT in screening programs in the United Kingdom since 2014 and in France since 2015[4].

Other non-invasive techniques are available, such as the fecal DNA analysis. These tests identify molecular alterations in adenomas and CRC cells. However, these tests are currently underused, due to the high cost and relatively low cost-effectiveness[20].

*Invasive techniques*

Flexible sigmoidoscopy screening was shown to be effective in reducing the incidence and mortality rates of CRC[21,22]. It should be taken into account that, when a distal adenomatous polyp is detected in a sigmoidoscopy, a colonoscopy is required. This is necessary, because the characteristics of adenomas found in the rectum and sigma are correlated with the probability of presenting a proximal CRC[2324].

Colonoscopy screening is used in several programs. Data are scarce from randomized clinical trials that have attested to its effectiveness. However, several observational studies have reported that colonoscopy screening reduced CRC mortality and incidence, mainly due to its great capacity for detecting neoplasias and adenomas. In a case-control study, performing a colonoscopy, regardless of its indication, was associated with a large reduction in the risk of CRC in the following 10 years after the test. This effect was greater when the colonoscopy had been used as a screening test[25]. Several cohort studies have confirmed this finding. One study showed that, in an average-risk population, performing a colonoscopy was associated with a 67% reduction in CRC incidence after an 8-year follow-up[26]. Another study demonstrated the long-term protective effect of a polypectomy. When a colonoscopy was performed with a polypectomy of at least one adenoma > 5 mm, the CRC incidence was reduced by 80% after a 10-year follow-up[27].

Colonoscopy quality has varied in reports from different endoscopists. For this reason, over the last decade, a series of quality indicators for colonoscopy have been described. However, application of these indicators has not become well established in endoscopic practice[28]. Currently, the main quality indicator among endoscopists is the adenoma detection rate (ADR). The ADR is defined as the proportion of screening colonoscopies performed by a physician that detected at least one histologically confirmed colorectal adenoma or adenocarcinoma. The recommended ADR is ≥ 25% (men ≥ 30%, women ≥ 20%)[29]. Several studies have demonstrated a strong correlation between the ADR record of an endoscopist and the probability of diagnosing CRC within a given number of months of a colonoscopy (an interval CRC) [24]. Despite the clinical importance of this measure, large variations remain among endoscopists.

One study analyzed the results of colonoscopies performed in the US through an integrated health services organization, over a 12-year period. The association between the ADR and the risk of diagnosing CRC within 6 months to 10 years after the first colonoscopy was evaluated, and the risk of death from cancer was calculated. They studied a total of 314,872 colonoscopies performed by 136 gastroenterologists, with ADRs that ranged from 7.4% to 52.5%. They identified 712 interval colorectal adenocarcinomas and 147 associated deaths. The gastroenterologists were placed into quintiles, based on their ADRs (lowest ADR quintile ≤ 19.06% and highest ADR quintile ≥ 33.51%). They found that patients examined by gastroenterologists in the lowest ADR quintile had almost double the risk of being diagnosed with an interval cancer compared to patients examined by gastroenterologists in the highest quintile. In addition, the risk of a fatal interval cancer was reduced by 62% among patients examined by gastroenterologists in the highest quintile. Each 1% increase in the ADR was associated with a 5% decrease in the risk of a fatal interval colorectal cancer[30].

Although the colonoscopy is more effective than the FOBT for detecting neoplasias and adenomas, the FOBT is more readily accepted by participants in population screening programs. Thus, the higher FOBT participation rates may counteract its lower detection capacity[31]. The COLONPREV study hypothesized that biennial FIT screening would be non-inferior to a one-time colonoscopy, for reducing CRC-related mortality among subjects with average risk. They recruited more than 50000 asymptomatic participants between ages 50 and 69 years, and randomly assigned them to undergo either a one-time colonoscopy or the biennial FIT. After the first round of FIT screening, they confirmed a similar CRC detection rate with both methods. However, advanced adenomas and other adenomas were detected at a higher rate in the colonoscopy than in the FIT groups. This result confirmed, once again, the superiority of the colonoscopy for detecting this type of lesion. Therefore, the colonoscopy has higher potential than the FIT for reducing the CRC incidence. Nevertheless, the higher participation rate in the FIT group (34.2% *vs* 24.6%), and the biennial periodicity of this test may reduce the apparent advantage of colonoscopy over the long term[32]. Final results from that study are expected in the next few years.

CRC SCREENING PROGRAMS

*CRC screening programs in Europe*

In 2003, based on compelling evidence, the Council of the European Union recommended that all Member States should establish early detection programs with CRC screening for men and women aged 50 to 74 years, with annual or biennial FOBTs, followed by colonoscopy, when the results were positive[33].Following this recommendation, several CRC screening programs were launched in Europe, with wide variations in screening practices, probably due to different preexisting screening programs (pilots, opportunity-based, or organized) in several countries. Variations among different countries also arose due to differences in financial resources available for research and differences in colonoscopy capacities.

In 2015, 24 countries in the European Union had established or were preparing to organize country-wide CRC screening programs. For example, Finland, France, Slovenia, and the United Kingdom had completely implemented organized programs. In Belgium, the Netherlands, Denmark, Ireland, Italy, Malta, Poland, and Spain, programs were being launched. Norway, Portugal, and Sweden were in the pilot phase. In contrast, other countries, including Slovakia, with the highest CRC rate in Europe[1], did not have a national screening program. Similarly, no screening programs existed in Bulgaria, Albania, Bosnia, Herzegovina, Kosovo, Macedonia, Montenegro, Romania, Serbia, and Russia[4].

An analysis of different programs in several European countries showed that Croatia and the Czech Republic had the lowest participation rates (< 25%), and both countries reported high ASRms (18.7% and 15.4%, respectively), followed by France (participation rate 34.3%). The other countries achieved better participation rates (over 45%); the highest participation was observed in the Netherlands, followed by Slovenia. The Netherlands had the highest positive test rate (test positivity, 12.2%), but the lowest cut-off value for the FIT test: 15 µg/g. The second highest test positivity was found in Ireland (10% test positivity, with a cut-off value 20 µg/g). In Italy, with the same cut-off value, test positivity was 5.8%, and in Slovenia, it was 5.9%. The lowest test positivity rates were found in England and France (2% and 2.8%, respectively), where the G-FOBT was used. In Croatia, Lithuania, and the Netherlands, the proportion of colonoscopies performed did not exceed 75%; but in the Czech Republic and Slovenia, the proportions were above 95%. In England, a very high CRC percentage was detected (10.1% of patients a with positive G-FOBT result), but only 2% of all patients had a positive G-FOBT. Ireland had a similar CRC percentage (9%), but also a greater number of patients had positive FIT results (10%). The highest detection rate was found in the Netherlands (5.9 per 1000 screenings), followed by Ireland (3.3 per 1000 screenings). More detailed results are described below and in Table 2.

**Spain:** Different screening programs have been implemented in all areas of Spain for the population aged 50-69 years. These programs mostly use the FIT. In 2014, participation rates varied among the regions, but the average was 49.2%. More women than men participated (51.41% *vs* 47.01%). On average, 6.56% of test results were positive, with a higher percentage found in men (8.2%) than in women (5.17%). The positive predictive value (PPV) for cancer was 4.70%. The CRC detection rate was 2.75 per 1000 screenings[34].

**The Netherlands:** In 2011, the Netherlands decided to implement a national population screening program for CRC. The program began in 2014, with the FIT test and a cut-off value of 15 µg/g. This program achieved a 68.2% participation rate. Initially, it was necessary to increase the cut-off value (from 15 μg/g to 47 μg/g ), because the proportion of individuals with positive tests was higher than expected (12%). This proportion exceeded the number of false positives, and it surpassed the capacity to perform colonoscopies. With the first cut-off value, test positivity was 10.1% in women and 14.5% in men. Colonoscopies were performed in 74.3% of these patients; among these, CRC was detected in 763 (6.7%) and advanced adenoma was detected in 33.5%. The CRC detection rate was 5.9 per 1000 inhabitants and the PPV was 6.7%[35].

**Ireland:** The first pilot program in Ireland was the Adelaide and Meath Hospital/Trinity College Dublin Colorectal Cancer Screening Program (TTC-CRC-SP).It included a population aged 50 to 74 years, and it applied the FIT (OC Sensor, cut-off value 20 μg/g). The participation rate was 51% (58% women and 42% men). The proportion of individuals with positive test results was 10%. Of the colonoscopies performed (87%), advanced adenomas were detected in 99 patients (24%) and CRC was detected in 38 (9%). The PPVs for CRC and advanced adenoma were 4% and 5%, respectively, and the CRC detection rate was 0.33%[36]. A second round was conducted, where they excluded patients that had changed residence, had been diagnosed with cancer, and had died. The participation rate was 48%, and 375 patients had positive test results (8%). Of the patients with a positive test, 87% underwent a colonoscopy. The PPV for CRC was similar to that of the first round (4%), and the CRC detection rate was 0.12%[37].

**Italy**:Lombardy is a densely populated northern region of Italy with the highest incidence of CRC. The screening program began with the population aged 50-69 years, in 2005-2006. They applied the FIT with a cut-off value of 20 μg/g. The second round of the program had been completed in 2009. The PPVs for advanced adenoma were 29% in the first round, and 30.2% in the second round. The PPVs for CRC were 4% and 3%, respectively. The PPVs for advanced adenoma and CRC were higher in people aged 60-69 years and in males. The CRC detection rates in the first and second rounds were 2.5 and 1.6 per 1000 screened, respectively[38].

**Croatia:** The Croatian screening program was implemented in 2007 for the population aged 50-74 years. They implemented the G-FOBT. Participation was low, reaching 19.9%. Positive tests were found in 6.9% cases, and of these, only 66% received a colonoscopy. CRC was identified in 472 patients (3.8%) [39].

**Lithuania:** The Lithuanian National Screening Program began in 2009, for the population aged 50 to 74 years. The FIT was applied. The participation rate for 3 years was 46% (271,396). A positive FIT was observed in 19455 participants (7.2%). Of these, 66.1% underwent a colonoscopy. High-grade neoplasia was detected in 3.9% of cases, and the rate of CRC was 3.1% among all colonoscopies. The rate of CRC detected with the program was 0.2%[40].

**Slovenia:** The Slovenian National Screening Program (SVIT program) started in 2009. This program performed a biennial FIT for the population aged 50 to 69 years during 2014. The participation rate was 57.8% (53.2% men, 62.3% women). In this population, 6% had positive test results (7.6% men and 4.7% women). The colonoscopies detected 159 (2.12%) patients with CRC and 1887 (25.16%) patients with advanced adenomas[41].

**England:** The English National Screening Program began in 2006 for the population aged 60 to 69 years. This program performed a biennial G-FOBT. The first round was completed in 2010. Of the 2 million invitations sent, 49.6% of men and 54.4% of women responded. The overall participation rate was 52%. Positive test results were found in 2% (2.5% men, 1.5% women). Among the colonoscopies performed (83%), CRC was detected in 10.1% (*n* = 1772; detection rates of 11.6% in men and 7.8% in women). High risk adenomas were detected in 9.8% (*n* = 1721; detection rates of 12.2% in men and 6.2% in women) [42].

**Czech Republic:** The Czech National Screening Program started in 2000 for individuals older than 50 years. They applied a biennial G-FOBT. By 2009, the FIT was introduced. The coverage of CRC screening in 2010 was 22.7%[43]. The results of the program from 2001 to 2011 are shown in Table 3.

**France:** The French National screening program started in 2008 for the population aged 50-74 years. They applied the G-FOBT. The participation rate was 34.3%. Positive test results were found in 2.8%. Of these, 88% underwent a colonoscopy. CRC was detected in 7.5% (detection was 9% in men and 5.8% in women). The advanced adenoma detection rate was 4.9 per 1000 screened; the CRC detection rate was 1.9‰[44].

*CRC screening programs in the Americas*

**United States:** Currently in the US, screening programs have been established on an opportunistic basis. The average-risk population (50-75 years) are encouraged to undergo screening at 50 years of age, and participants choose among several options. The available options are: (1) annual G-FOBT or FIT, according to the manufacturer's recommendations for specimen collection; (2) multi-target stool DNA test every 3 years; (3) flexible sigmoidoscopy every 5 years; (4) colonoscopy every 10 years; (5) double-contrast barium enema every 5 years; or (6) CT colonography every 5 years. In about 90% of cases, colonoscopy is the preferred option[28].

On the other hand, screening program evaluations have been conducted in several regions of the country. For example, the Kaiser Permanente Northern and Southern California program conducted 4 screening rounds in a population of 50 to 70 years. They used the annual FIT (cut-off value 20 μg/g). They achieved a 48.2% participation rate in the first round. A positive FIT result was found in 5% of participants and the PPVs were 51.5% for adenomas and 3.4% for CRC[45].

**Canada:** Canada organized a CRC screening program for average-risk individuals, aged 50-74 years, from January 2009 to December 2011. Five provincial programs were included (British Columbia, Saskatchewan, Manitoba, Nova Scotia, and Prince Edward Island). The results of the first round showed very low participation rates (16.1%)[46]. The test positivity rate was 4.4% (4.8% with FIT and 3.7% with G-FOBT). Positive test results were more frequent in men (5.9%) than in women (3.4%), and the frequency increased with age: positive tests were found in 5.7% of the 70–74 age group and 3.4% of the 50–54 age group. Compliance with a follow-up colonoscopy was 80.5%. The detection rates were 16.9 per 1000 screened for adenomas, and 1.8 per 1000 screened for CRC. The PPVs for adenoma were 35.9% with the G-FOBT and 50.6% with the FIT. The PPV for CRC was 4.4% in both tests.

**Chile:** In Chile, an organized screening program was launched between 2007 and 2009 in asymptomatic subjects, aged 50 years or older without risk factors. They applied the FIT test with a cutoff of 20 μg/g. The participation rate was 77%. Of 4,938 participants, positive test results were found in 9.6%. Of these, a colonoscopy was performed in 58.6%. CRC detection rates were 2 per 1000 screenings[47].

*CRC screening programs in the western pacific and east asia*

The Asian Pacific Colorectal Cancer Working Group has recommended organized screening in regions with the highest CRC incidence (> 30 per 100000)[48]. The programs target average-risk individuals, aged 50-75 years, and they preferably apply the FIT test. Several studies have investigated the barriers to CRC detection in different cultural and socio-political contexts in the Asia-Pacific region. These barriers included poor understanding of the characteristics of screening and testing, lack of financial support, and lack of health insurance[49]. Several countries in East Asia have ongoing organized screening programs, including Japan, Korea, China, Hong Kong, Taiwan, and Bangkok[50]. The results for several of these CRC Screening Programs are described below.

**Japan:** In Japan, a CRC screening program has been in place since 1992 for beneficiaries of health insurance, aged 40-69 years. The program applies the FIT. In 2013, participation rates were 41.4% in men and 34.5% in women[51].

**South Korea:** The South Korean National Screening Program was introduced in 2004. It targets the National Health Insurance population, aged over 50 years. They employ an annual FIT (qualitative or quantitative). Participation increased from 10.5% in 2004 to 21.1% in 2008and to 25% in 2012[52]. In 2008, the FIT positivity rate was 7.5% (8.8% in men and 6.4% in women). A colonoscopy was performed in 31.4% of those with positive test results. The CRC detection rate was 1.2%[53].

**Taiwan:** The Taiwanese National program began in 2004. They performed biennial FITs in individuals aged 50 to 69 years. In the first round, 1160895 individuals (21.4%) participated. The test positivity rate was 4%. Subsequent colonoscopies detected 4284 advanced adenomas (detection rate 4.6 per 1000) and 2304 CRCs (detection rate 2.5 per 1000). The PPVs of FITs were 11.7% for advanced adenoma, and 6.1% for CRC[54].

**Thailand:** A Thai pilot screening program was implemented in 2011. The FIT was performed in the population aged 50-65 years in Lampang Province. The participation rate (62.9%) was higher among women (67.8%) than men (57.8%). The test was positive in 1.1% (1.2% men, 1.0% women). Colonoscopy was performed in 72% of those with positive tests. Detection rates were 3.7% for CRC and 30.6% for adenomas[55].

**Australia:** An Australian pilot program was conducted from 2002 to 2006 with the biennial FIT in the population aged 55-74 years. The participation rate was 45.4% (women 47.4%, men 43.4%). Positive FIT results were found in 9% of participants. Colonoscopy was performed in 54.8% of the individuals with positive FITs. Adenomas were found in 19.8% (13.9% advanced) and CRC was found in 5.3%[56]. In 2006, The National Bowel Cancer Screening Program was initiated with a biennial FIT for the population aged 55-65 years. The program will continue to expand until 2020. The program aims to apply biennial screening to the entire population aged 50-74 years[4].

COMPARISON OF THE RESULTS OF SEVERAL CRC SCREENING PROGRAMS

Most European countries have implemented a national organized screening program. However, some countries have not, despite high CRC incidence and mortality rates, such as Slovakia. Likewise, most countries of Central America, South America, the Middle East, and Africa, do not have organized screening programs. In most cases, the lack of organized programs could be explained by limited resources, including the limited availability of colonoscopy facilities, and the type of organization of the Health Care System. Most organized screening programs use non-invasive tests (FIT or G-FOBT); in contrast, most opportunistic programs rely on endoscopy. Colonoscopy remains the most commonly used screening test in North America, but FIT screening programs are beginning to be implemented in some areas, such as California[45].

The efficacy of CRC screening is determined by the degree of participation and the diagnostic yield of the test. Studies have shown that FIT screening is superior to G-FOBT in both aspects[20,47]. The overall results showed that the highest participation rates were obtained in programs using FIT. In fact, in programs that used both tests (FIT and G-FOBT), participation rates increased after FIT was introduced, as observed in the Czech Republic[43].

FIT screening also produced more positive tests than G-FOBT screening. Therefore, the lowest rates of test positivity in Europe were obtained in England and France, where screening was performed with the G-FOBT[42,44]. As mentioned, in the Czech Republic program, after the G-FOBT was replaced with the FIT, the PPV for advanced adenoma increased, and the PPV for CRC decreased[43]. This result implied that, compared to the G-FOBT, the FIT had a higher sensitivity and PPV for advanced adenomas, but a lower PPV for CRC.

Among all the programs reviewed, only Korea used a qualitative FIT. Studies worldwide using different Hb thresholds have shown that defining a positive FIT result with a cut-off value of 100 ng/mL Hb (20 μg/g) provided high sensitivity, specificity, and PPV for detecting neoplasia[49,,53,54]. Other studies reported a decline in specificity with cut-off values below 100 ng/ml Hb[5,45,46,48,53]. According to this information, a cutoff value between 75 and 100 ng/mL Hb might represent an optimum in most European populations, depending on the resources and availability of colonoscopy.

Some countries had to modify the cut-off value to align the need for colonoscopies with the limited capacity of endoscopic resources. For example, in the Netherlands, which had the highest rates of positivity among all international and European programs, the cutoff value was raised from 88 to 275 ng/ml Hb (15 μg/g to 47 μg/g) at the beginning of their program[35]. In addition, the Netherlands had the highest CRC detection rate in Europe; the detection rates were double those of several European and other countries. The program in Ireland also had a high percentage of positive tests (10%). In comparison, with the same cut-off value, Italy had almost half (5.8%) the proportion of positive tests. This suggested that there might be a relatively high incidence of adenomas in Ireland, and that lower cut-off values would be very difficult to manage with the current availability of colonoscopy resources in the country.

Another problem to consider is the low acceptance of colonoscopy in some countries. In South Korea, only 31.4% of individuals with a positive FIT had undergone a colonoscopy after. This reluctance could result in low detection rates[53]. In other European countries, like Croatia, Lithuania, and The Netherlands, the proportion of colonoscopies among individuals with positive test results did not exceed 75%[35,39,40].

Participation rates in the screening programs were higher among women than men. This difference probably occurred because women had a greater awareness of preventive programs; in particular, women were likely to have had experience in breast and cervix screening. In addition, positive FIT rates were significantly higher in men than in women (except in Ireland and Thailand, where rates were similar between the sexes). The CRC detection rates were also higher in men than in women; in some programs, detection rates in men were double the rates in women. Special efforts should be made in all screening programs to increase both the overall participation and male participation rates.

The lowest participation rates were found in Canada, possibly because the data were published recently after the programs had been started.

In general, participation rates in the different programs currently exceed the acceptable minimum of 45%, but they have not reached the desired target (> 65%). Screening programs must employ specific strategies to attract the target population and encourage participation in screening programs. A better understanding of the barriers and facilitators to participation is needed to design strategies that promote equity of access. It is important to monitor, record, and evaluate the minimum indicators and requirements of CRC Population Screening Programs, to ensure they meet the standards of the European Quality Control Guide.

CONCLUSION

This review highlighted the large variations in CRC incidence and mortality around the world. Some regions with high CRC rates do not have screening programs, and other regions, like Europe, have widespread organized screening programs. Additionally, participation rates vary greatly between programs around the world. The highest rates were found in the Netherlands and the lowest were found in Canada. The most common test used as a screening tool in organized screening programs was the fecal occult blood test. In countries with screening programs that arose opportunistically, colonoscopy was most commonly used for screening. Between the two types of fecal occult blood tests, the most commonly used test was the FIT. Use of the FIT has increased participation rates, because it is user friendly; a single sample suffices, and no dietary restrictions are imposed prior to the test. Because the FIT is more sensitive than the G-FOBT, the number of false positives and the demand for invasive tests has increased. Consequently, the cut-off value of the test must be adapted to each region, taking into account the availability of endoscopic resources. The FIT also exhibited superior detection of advanced adenomas compared to the G-FOBT. This feature promotes treatment in early stages and prevents the formation of cancer. Participation rates were higher among women, possibly due to their increased awareness of the importance of other screening programs, such as breast cancer screening. Positive test results and CRC detection rates were higher in men than in women; therefore, men’s awareness should be increased to encourage participation in screening programs.

**REFERENCES**

1 **Globocan**. Estimated cancer incidence, mortality and prevalence worldwide in 2012. (2012). Avaiable from: URL: http: //globocan.iarc.fr/Default.aspx

2 **Forman D**, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, Steliarova-Foucher E, Swaminathan R, Ferlay J. Cancer incidence in five continents. Vol X. International Agency for Research on Cancer, 2014.

3 **Ferlay J**, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer* 2010; **127**: 2893-2917 [PMID: 21351269 DOI: 10.1002/ijc.25516]

4 **Schreuders EH**, Ruco A, Rabeneck L, Schoen RE, Sung JJ, Young GP, Kuipers EJ. Colorectal cancer screening: a global overview of existing programmes. *Gut* 2015; **64**: 1637-1649 [PMID: 26041752 DOI: 10.1136/gutjnl-2014-309086]

5 **Siegel RL**, Miller KD, Jemal A. Cancer statistics, 2016. *CA Cancer J Clin* ; **66**: 7-30 [PMID: 26742998 DOI: 10.3322/caac.21332]

6 **Winawer SJ**, Zauber AG, Ho MN, O'Brien MJ, Gottlieb LS, Sternberg SS, Waye JD, Schapiro M, Bond JH, Panish JF. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. *N Engl J Med* 1993; **329**: 1977-1981 [PMID: 8247072 DOI: 10.1056/NEJM199312303292701]

7 **Stryker SJ**, Wolff BG, Culp CE, Libbe SD, Ilstrup DM, MacCarty RL. Natural history of untreated colonic polyps. *Gastroenterology* 1987; **93**: 1009-1013 [PMID: 3653628]

8 **Wilson JMG,** Jungner G. Principles and practice of screening for disease. Geneva: WHO; 1968. Available from: URL: http: //www.who.int/bulletin/volumes/86/4/07-050112BP.pdf

9 **Andermann A**, Blancquaert I, Beauchamp S, Déry V. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. *Bull World Health Organ* 2008; **86**: 317-319 [PMID: 18438522 DOI: 10.2471/BLT.07.050112]

10 **Pignone M**, Saha S, Hoerger T, Mandelblatt J. Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force. *Ann Intern Med* 2002; **137**: 96-104 [PMID: 12118964 DOI: 10.7326/0003-4819-137-2-200207160-00007]

11 **Castells A**, Marzo-Castillejo M, Mascort J, Amador F, Andreu M, Bellas B. Guía de práctica clínica en prevención del cáncer colorectal. *Gastroenterol Hepatol* 2009; **32**: 717.e1-717.e58 [DOI: http://dx.doi.org/10.1016/j.gastrohep.2009.09.001]

12 **Hewitson P**, Glasziou P, Watson E, Towler B, Irwig L. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. *Am J Gastroenterol* 2008; **103**: 1541-1549 [PMID: 18479499 DOI: 10.1111/j.1572-0241.2008.01875.x]

13 **Shaukat A**, Mongin SJ, Geisser MS, Lederle FA, Bond JH, Mandel JS, Church TR. Long-term mortality after screening for colorectal cancer. *N Engl J Med* 2013; **369**: 1106-1114 [PMID: 24047060 DOI: 10.1056/NEJMoa1300720]

14 **Mandel JS**, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ, Snover DC, Schuman LM. The effect of fecal occult-blood screening on the incidence of colorectal cancer. *N Engl J Med* 2000; **343**: 1603-1607 [PMID: 11096167 DOI: 10.1056/NEJM200011303432203]

15 **van Rossum LG**, van Rijn AF, Laheij RJ, van Oijen MG, Fockens P, van Krieken HH, Verbeek AL, Jansen JB, Dekker E. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. *Gastroenterology* 2008; **135**: 82-90 [PMID: 18482589 DOI: 10.1053/j.gastro.2008.03.040]

16 **Parra-Blanco A**, Gimeno-García AZ, Quintero E, Nicolás D, Moreno SG, Jiménez A, Hernández-Guerra M, Carrillo-Palau M, Eishi Y, López-Bastida J. Diagnostic accuracy of immunochemical versus guaiac faecal occult blood tests for colorectal cancer screening. *J Gastroenterol* 2010; **45**: 703-712 [PMID: 20157748 DOI: 10.1007/s00535-010-0214-8]

17 **Grazzini G**, Visioli CB, Zorzi M, Ciatto S, Banovich F, Bonanomi AG, Bortoli A, Castiglione G, Cazzola L, Confortini M, Mantellini P, Rubeca T, Zappa M. Immunochemical faecal occult blood test: number of samples and positivity cutoff. What is the best strategy for colorectal cancer screening? *Br J Cancer* 2009; **100**: 259-265 [PMID: 19142185 DOI: 10.1038/sj.bjc.6604864]

18 **Hamza S**, Dancourt V, Lejeune C, Bidan JM, Lepage C, Faivre J. Diagnostic yield of a one sample immunochemical test at different cut-off values in an organised screening programme for colorectal cancer. *Eur J Cancer* 2013; **49**: 2727-2733 [PMID: 23601670 DOI: 10.1016/j.ejca.2013.03.023]

19 **Tinmouth J**, Lansdorp-Vogelaar I, Allison JE. Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know. *Gut* 2015; **64**: 1327-1337 [PMID: 26041750 DOI: 10.1136/gutjnl-2014-308074]

20 **National Cancer Institute.** Colorectal Cancer Prevention. Available from: URL: http: // www.cancer.gov

21 **Atkin WS**, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover JM, Parkin DM, Wardle J, Duffy SW, Cuzick J. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. *Lancet* 2010; **375**: 1624-1633 [PMID: 20430429 DOI: 10.1016/S0140-6736(10)60551-X]

22 **Brenner H**, Stock C, Hoffmeister M. Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies. *BMJ* 2014; **348**: g2467 [PMID: 24922745 DOI: 10.1136/bmj.g2467]

23 **Zarchy TM**, Ershoff D. Do characteristics of adenomas on flexible sigmoidoscopy predict advanced lesions on baseline colonoscopy? *Gastroenterology* 1994; **106**: 1501-1504 [PMID: 8194695]

24 **Papatheodoridis GV**, Triantafyllou K, Tzouvala M, Paspatis G, Xourgias V, Karamanolis DG. Characteristics of rectosigmoid adenomas as predictors of synchronous advanced proximal colon neoplasms. *Am J Gastroenterol* 1996; **91**: 1809-1813 [PMID: 8792703]

25 **Brenner H**, Chang-Claude J, Jansen L, Knebel P, Stock C, Hoffmeister M. Reduced risk of colorectal cancer up to 10 years after screening, surveillance, or diagnostic colonoscopy. *Gastroenterology* 2014; **146**: 709-717 [PMID: 24012982 DOI: 10.1053/j.gastro.2013.09.001]

26 **Kahi CJ**, Imperiale TF, Juliar BE, Rex DK. Effect of screening colonoscopy on colorectal cancer incidence and mortality. *Clin Gastroenterol Hepatol* 2009; **7**: 770-75; quiz 711 [PMID: 19268269 DOI: 10.1016/j.cgh.2008.12.030]

27 **Citarda F**, Tomaselli G, Capocaccia R, Barcherini S, Crespi M. Efficacy in standard clinical practice of colonoscopic polypectomy in reducing colorectal cancer incidence. *Gut* 2001; **48**: 812-815 [PMID: 11358901 DOI: 10.1136/gut.48.6.812]

28 **Smith RA**, Andrews K, Brooks D, DeSantis CE, Fedewa SA, Lortet-Tieulent J, Manassaram-Baptiste D, Brawley OW, Wender RC. Cancer screening in the United States, 2016: A review of current American Cancer Society guidelines and current issues in cancer screening. *CA Cancer J Clin* ; **66**: 96-114 [PMID: 26797525 DOI: 10.3322/caac.21336]

29 **Rex DK**, Schoenfeld PS, Cohen J, Pike IM, Adler DG, Fennerty MB, Lieb JG, Park WG, Rizk MK, Sawhney MS, Shaheen NJ, Wani S, Weinberg DS. Quality indicators for colonoscopy. *Am J Gastroenterol* 2015; **110**: 72-90 [PMID: 25448873 DOI: 10.1038/ajg.2014.385]

30 **Corley DA**, Jensen CD, Marks AR, Zhao WK, Lee JK, Doubeni CA, Zauber AG, de Boer J, Fireman BH, Schottinger JE, Quinn VP, Ghai NR, Levin TR, Quesenberry CP. Adenoma detection rate and risk of colorectal cancer and death. *N Engl J Med* 2014; **370**: 1298-1306 [PMID: 24693890 DOI: 10.1056/NEJMoa1309086]

31 **Segnan N**, Senore C, Andreoni B, Azzoni A, Bisanti L, Cardelli A, Castiglione G, Crosta C, Ederle A, Fantin A, Ferrari A, Fracchia M, Ferrero F, Gasperoni S, Recchia S, Risio M, Rubeca T, Saracco G, Zappa M. Comparing attendance and detection rate of colonoscopy with sigmoidoscopy and FIT for colorectal cancer screening. *Gastroenterology* 2007; **132**: 2304-2312 [PMID: 17570205 DOI: 10.1053/j.gastro.2007.03.030]

32 **Quintero E**, Castells A, Bujanda L, Cubiella J, Salas D, Lanas Á, Andreu M, Carballo F, Morillas JD, Hernández C, Jover R, Montalvo I, Arenas J, Laredo E, Hernández V, Iglesias F, Cid E, Zubizarreta R, Sala T, Ponce M, Andrés M, Teruel G, Peris A, Roncales MP, Polo-Tomás M, Bessa X, Ferrer-Armengou O, Grau J, Serradesanferm A, Ono A, Cruzado J, Pérez-Riquelme F, Alonso-Abreu I, de la Vega-Prieto M, Reyes-Melian JM, Cacho G, Díaz-Tasende J, Herreros-de-Tejada A, Poves C, Santander C, González-Navarro A. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. *N Engl J Med* 2012; **366**: 697-706 [PMID: 22356323 DOI: 10.1056/NEJMoa1108895]

33 **Council of the European Union**. Council Recommendation of 2 December 2003 on Cancer Screening (2003/878/EC) 878. Off J Eur Union; 2003.

34 **Red de programas de cribado de cáncer.** Available from: URL: http: //www.cribadocancer.com

35 **Heijnen ML,** Landsdorp-Vogelaar I. CRC Screening in the Netherlands. From pilot to National Programme. 2014. Available from: URL: http: //www.rivm.nl/en/Topics/B/Bowel\_cancer\_screening\_programme.

36 **McNamara D**, Qasim A, Lee N, Condon C, O'Morain C. Round one of the Adelaide and Meath Hospital/Trinity College Colorectal Cancer Screening Programme: programme report and analysis based on established international key performance indices. *Ir J Med Sci* 2011; **180**: 549-552 [PMID: 21264524 DOI: 10.1007/s11845-010-0650-8]

37 **McNamara D**, Leen R, Seng-Lee C, Shearer N, Crotty P, Neary P, Walsh P, Boran G, O'Morain C. Sustained participation, colonoscopy uptake and adenoma detection rates over two rounds of the Tallaght-Trinity College colorectal cancer screening programme with the faecal immunological test. *Eur J Gastroenterol Hepatol* 2014; **26**: 1415-1421 [PMID: 25244415 DOI: 10.1097/MEG.0000000000000207]

38 **Parente F**, Boemo C, Ardizzoia A, Costa M, Carzaniga P, Ilardo A, Moretti R, Cremaschini M, Parente EM, Pirola ME. Outcomes and cost evaluation of the first two rounds of a colorectal cancer screening program based on immunochemical fecal occult blood test in northern Italy. *Endoscopy* 2013; **45**: 27-34 [PMID: 23254404 DOI: 10.1055/s-0032-1325800]

39 **Katicic M,** Antoljak N, Kujundžić M, Stamenić V, Skoko Poljak D, Kramarić D, Stimac D, Strnad Pešikan M, Samija M, Ebling Z. Results of National Colorectal Cancer  Screening Program in Croatia (2007–2011). *World J Gastroenterol* 2012; **18**: 4300–4307 [PMID: 22969192 DOI: 10.3748/wjg.v18.i32.4300].

40 **Poskus T**, Strupas K, Mikalauskas S, Bitinaitė D, Kavaliauskas A, Samalavicius NE, Saladzinskas Z. Initial results of the National Colorectal Cancer Screening Program in Lithuania. *Eur J Cancer Prev* 2015; **24**: 76-80 [PMID: 25370682 DOI: 10.1097/CEJ.0000000000000096]

41 **SVIT Programme**: **Screening for colorectal Cancer.** Republic of Slovenia. Ministry of health. Available from: URL: http: //www.dpor.si.

42 **Logan RF**, Patnick J, Nickerson C, Coleman L, Rutter MD, von Wagner C. Outcomes of the Bowel Cancer Screening Programme (BCSP) in England after the first 1 million tests. *Gut* 2012; **61**: 1439-1446 [PMID: 22156981 DOI: 10.1136/gutjnl-2011-300843]

43 **Suchanek S**, Majek O, Vojtechova G, Minarikova P, Rotnaglova B, Seifert B, Minarik M, Kozeny P, Dusek L, Zavoral M. Colorectal cancer prevention in the Czech Republic: time trends in performance indicators and current situation after 10 years of screening. *Eur J Cancer Prev* 2014; **23**: 18-26 [PMID: 24129196 DOI: 10.1097/CEJ.0b013e328364f203]

44 **Leuraud K**, Jezewski-Serra D, Viguier J, Salines E. Colorectal cancer screening by guaiac faecal occult blood test in France: Evaluation of the programme two years after launching. *Cancer Epidemiol* 2013; **37**: 959-967 [PMID: 24035240 DOI: 10.1016/j.canep.2013.07.008]

45 **Jensen CD**, Corley DA, Quinn VP, Doubeni CA, Zauber AG, Lee JK, Zhao WK, Marks AR, Schottinger JE, Ghai NR, Lee AT, Contreras R, Klabunde CN, Quesenberry CP, Levin TR, Mysliwiec PA. Fecal Immunochemical Test Program Performance Over 4 Rounds of Annual Screening: A Retrospective Cohort Study. *Ann Intern Med* 2016; **164**: 456-463 [PMID: 26811150 DOI: 10.7326/M15-0983]

46 **Major D**, Bryant H, Delaney M, Fekete S, Gentile L, Harrison M, Mai V, Nicholson E, Taylor Y. Colorectal cancer screening in Canada: results from the first round of screening for five provincial programs. *Curr Oncol* 2013; **20**: 252-257 [PMID: 24155629 DOI: 10.3747/co.20.1646]

47 **López-Kostner F**, Kronberg U, Zarate AJ Cortés M. Programa de detección de neoplasias colorrectales en población mayor de 50 años. *Rev Med Chile* 2012; **140**: 281-286 [DOI: 10.4067/S0034-9887201200030000].

48 **Sung JJ**, Ng SC, Chan FK, Chiu HM, Kim HS, Matsuda T, Ng SS, Lau JY, Zheng S, Adler S, Reddy N, Yeoh KG, Tsoi KK, Ching JY, Kuipers EJ, Rabeneck L, Young GP, Steele RJ, Lieberman D, Goh KL. An updated Asia Pacific Consensus Recommendations on colorectal cancer screening. *Gut* 2015; **64**: 121-132 [PMID: 24647008 DOI: 10.1136/gutjnl-2013-306503]

49 **Cai SR**, Zhang SZ, Zhu HH, Zheng S. Barriers to colorectal cancer screening: a case-control study. *World J Gastroenterol* 2009; **15**: 2531-2536 [PMID: 19469005 DOI: 10.3748/wjg.15.2531]

50 **Sano Y**, Byeon JS, Li XB, Wong MC, Chiu HM, Rerknimitr R, Utsumi T, Hattori S, Sano W, Iwatate M, Chiu P, Sung J. Colorectal cancer screening of the general population in East Asia. *Dig Endosc* 2016; **28**: 243-249 [PMID: 26595883 DOI: 10.1111/den.12579]

51 **Center for cancer control and information services NCC.** Cancer statistics in Japan ’13. Japan: foundation for promotion of cancer research, 2013. Available from: URL: http: // www.ncc.go.jp/en/cis/index.html

52 **Suh M**, Song S, Cho HN, Park B, Jun JK, Choi E, Kim Y, Choi KS. Trends in Participation Rates for the National Cancer Screening Program in Korea, 2002-2012. *Cancer Res Treat* 2016; : [PMID: 27857022 DOI: 10.4143/crt.2016.186]

53 **Choi KS**, Lee HY, Jun JK, Shin A, Park EC. Adherence to follow-up after a positive fecal occult blood test in an organized colorectal cancer screening program in Korea, 2004-2008. *J Gastroenterol Hepatol* 2012; **27**: 1070-1077 [PMID: 22004224 DOI: 10.1111/j.1440-1746.2011.06944.x]

54 **Chiu HM**, Chen SL, Yen AM, Chiu SY, Fann JC, Lee YC, Pan SL, Wu MS, Liao CS, Chen HH, Koong SL, Chiou ST. Effectiveness of fecal immunochemical testing in reducing colorectal cancer mortality from the One Million Taiwanese Screening Program. *Cancer* 2015; **121**: 3221-3229 [PMID: 25995082 DOI: 10.1002/cncr.29462]

55 **Khuhaprema T**, Sangrajrang S, Lalitwongsa S, Chokvanitphong V, Raunroadroong T, Ratanachu-Ek T, Muwonge R, Lucas E, Wild C, Sankaranarayanan R. Organised colorectal cancer screening in Lampang Province, Thailand: preliminary results from a pilot implementation programme. *BMJ Open* 2014; **4**: e003671 [PMID: 24435889 DOI: 10.1136/bmjopen-2013-003671]

56 **Commonwealth of Australia.** The Australian bowel Cancer Screening Pilot Program and Beyond, 2005. Screening monograph no.6/2005. Available from: URL: http: //www.cancerscreening.gov.au/internet/screening/publishing.nsf/content/9C0493AFEB3FD33CCA257D720005C9F2/$File/final-eval.pdf

**P-Reviewer:** Bechtold ML, Cho YS, Lakatos PL **S-Editor:** Qi Y **L-Editor: E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** Spain

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 New screening criteria (Adapted from: Andermann *et al***[**9**]

|  |
| --- |
| **Emerging screening criteria proposed after Wilson and Junger principles** |
| The screening programme should respond to a recognized need. |
| The objectives of screening should be defined at the outset. |
| There should be a defined target population. |
| There should be scientific evidence of screening programme effectiveness. |
| The programme should integrate education, testing, clinical services and programme management. |
| There should be quality assurance, with mechanisms to minimize potential risks of screening. |
| The programme should ensure informed choice, confidentiality and respect for autonomy. |
| The programme should promote equity and access to screening for the entire target population. |
| Programme evaluation should be planned from the outset. |
| The overall benefits of screening should outweigh the harm |

**Table 2 Results of European Screening Programs**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Country** | **Netherlands** | **Italy** | **Ireland** | **Lithuania** | **Croatia** | **Czech Republic** | **Slovenia** | **England** | **France** |
| ASRi | 40.2 | 33.9 | 34.9 | 23.4 | 32.9 | 39.9 | 37 | 30.2 | 36.1 |
| ASRm | 13.4 | 10.8 | 12.2 | 13.7 | 18.7 | 15.4 | 16.2 | 10.7 | 12.9 |
| Period | 2014-2015 | 2007-2009 | 2008-2009 | 2009-2012 | 2007-2011 | 2000-2011 | 2009-2014 | 2006-2010 | 2008-2009 |
| Age | 55-75 | 50-69 | 50-74 | 50-74 | 50-74 | >50 | 50-69 | 60-69 | 50-74 |
| Test | FIT | FIT | FIT | FIT | gFOBT | gFOBT/FIT | FIT | gFOBT | gFOBT |
| Participation, *n* (%)  M, *n* (%)  F , *n* (%) | 129,395 (68.2) | 81619  (54.4) | 9993  (51)  2126 (42%)  2937 (42%) | 271396  (46) | 210239 (19.9) | 521,429  (22.7) | 152475 (60.43)  55.23%  65.53% | 1079293  (52)  510,864 (49.6%)  568,429 (54.4%) | 2,964,976 (34.3)  32.1%  36.2% |
| Positive test, *n* (%)  M, *n* (%)  F, *n* (%) | 15,802  (12.2)  14.5%  10.1% | (5.8) | 514 (10)  254 (5)  260 (5) | 19,455  (7.2) | 12,477 (6.9) | 31,794  (6.1) | 8108 (5.9)  7.6%  4.7% | 21106 (2%)  12776 (2.5)  8330 (1.5) | 82786 (2.8)  3.3%  2.4% |
| Colonoscopies performed | 74.3% | 92.5% | 87% | 66.1% | 66% | 95.7% | 98.9% | 83% | 88.4% |
| Advanced adenomas, *n* (%) | 3832  (33.5) | 702 | 99  (24) | 3.9% | 41% | 3077 | 1887 (25.16) | 1721  (9.8) | 14276 |
| PPV Advanced adenomas | NA | 30.2% | 5% | NA | NA | 16.8% | NA | NA | 19.6% |
| CRC, *n* (%) | 763 (6.7) | 70 | 38 (9) | 3.1% | 472 (3.6) | 829 | 159 (2.16) | 1772 (10.1) | 7.5% |
| PPV CRC | 6.7% | 3% | 4% | NA | NA | 4.5% | NA | NA | NA |
| CRC detection rate per 1000 | 5.9 | 1.6 | 3.3 | 0.2 | NA | 1 | NA | NA | 1.9 |

NA: Not available.

**Table 3 Results of CRC screening program time-trend (adapted from Suchanek S *et al*)[43]**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **2006** | **2007** | **2008** | **2009** | **2010** | **2011** | **Total** |
| Examined patients (*n*) | 272658 | 320317 | 352595 | 414300 | 521429 | NA | 1881299 |
| Positivity rate | 3.6% | 3.3% | 4.1% | 5.0% | 6.1% | NA | 4.6% |
| PPV for advanced adenoma | 14.1% | 13.5% | 16.2% | 16.6% | 16.8% | 16.7% | 16.2% |
| PPV for CRC | 6.3% | 5.9% | 6.0% | 5.1% | 4.5% | 3.6% | 4.8% |

## 

## **Table 4 Results of American, Western Pacific and East Asian screening programs**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Country** | **Canada** | **California (United States)** | **South Korea** | **Australia** | **Thailand** | **Taiwan** | **Chile** |
| ASRi | 35.5 | 25 (United States) | 45 | 38 | 12.4 | NA | 15 |
| ASRm | 10.8 | 9.2 (United States) | 12 | 9 | 7.3 | NA | 8.6 |
| Period | 2009-2011 | 2008 | 2004-2008 | 2002-2004 | 2011-2012 | 2004-2009 | 2007-2009 |
| Age range | 50-74 | 50-70 | 50-75 | 55-74 | 50-65 | 50-69 | > 50 |
| Test | G-FOBT/FIT | FIT | FIT | FIT | FIT | FIT | FIT |
| Participation, *n* (%)  M, *n* (%)  F, *n* (%) | 104750  (16.1) | 323349 (48.2) | 984915 (21)  446590 (20.5)  538325 (21.9) | 25840 (45.4) | 80012 (62.9)  57.8%  67.8% | 1160895 (21.4)  446290 (20.4)  714605 (25) | 4938 |
| Positive test, *n* (%)  M, *n* (%)  F, *n* (%) | 4661 (4.4)  5.9%  3.4% | 5% | 73568  (7.5)  39233 (8.8)  34335 (6.4) | 2308 (8.9) | 873 (1.1)  1.2%  1.1% | 4%  5%  3.4% | 476 (9.6) |
| Colonoscopies performed | 80.5% | NA | 23,117 (31.4) | 1265 (54.8) | 627 (71.8) | 80% | 279 (58.6) |
| Advanced adenoma, *n* (%) | NA | NA | NA | 176 (13.9) | 75 (12%) | 4284 | 75 (16) |
| PPV Advanced adenoma | NA | NA | NA | NA | NA | NA | NA |
| CRC, *n* (%)  PPV CRC | 86  4.4% | 3.4% | 1.2% | 67 (5.3) | 23 (3.7) | 2304 | 13 (1.1) |
| CRC Detection rate per 1000 | 1.8 | NA | NA | 2.59 | 0.29 | 2.5 | 2 |